Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000825485 | SCV000966788 | uncertain significance | not specified | 2018-03-12 | criteria provided, single submitter | clinical testing | The p.Leu452ProfsX60 variant in TYMP has not been previously reported in individ uals with disease, but has been identified in 0.026% (6/22794) of Finnish chromo somes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.o rg; dbSNP 772501604). This variant is predicted to remove the last 33 amino acid s of the protein and replace it with a different 60 amino acids. The tail end of the protein is not conserved in mammals, and thus it is unclear what the functi onal effect will be by altering the end of the protein. In summary, the clinical significance of the p.Leu452ProfsX60 variant in TYMP is uncertain. ACMG/AMP Cri teria applied: PM3 |
Labcorp Genetics |
RCV001869265 | SCV002242708 | pathogenic | not provided | 2022-11-08 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the TYMP gene (p.Leu447Profs*?). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 36 amino acid(s) of the TYMP protein and extend the protein by an uncertain number of additional additional amino acid residues. For these reasons, this variant has been classified as Pathogenic. This variant results in an extension of the TYMP protein. Other variant(s) that result in a similarly extended protein product (p.Phe473Serfs*?) have been determined to be pathogenic (PMID: 21412940). This suggests that these extensions are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 666945). This frameshift has been observed in individual(s) with clinical features of TYMP-related conditions (Invitae). This variant is present in population databases (rs772501604, gnomAD 0.03%). |